Literature DB >> 32768179

Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance.

Pavel S Roshanov1, John W Eikelboom2, Daniel I Sessler3, Clive Kearon4, Gordon H Guyatt5, Mark Crowther6, Vikas Tandon6, Flavia Kessler Borges2, Andre Lamy7, Richard Whitlock8, Bruce M Biccard9, Wojciech Szczeklik10, Mohamed Panju6, Jessica Spence11, Amit X Garg12, Michael McGillion13, Tomas VanHelder14, Peter A Kavsak15, Justin de Beer16, Mitchell Winemaker16, Yannick Le Manach17, Tej Sheth6, Jehonathan H Pinthus16, Deborah Siegal6, Lehana Thabane18, Marko R I Simunovic7, Ryszard Mizera6, Sebastian Ribas6, Philip J Devereaux19.   

Abstract

BACKGROUND: We aimed to establish diagnostic criteria for bleeding independently associated with mortality after noncardiac surgery (BIMS) defined as bleeding during or within 30 days after noncardiac surgery that is independently associated with mortality within 30 days of surgery, and to estimate the proportion of 30-day postoperative mortality potentially attributable to BIMS.
METHODS: This was a prospective cohort study of participants ≥45 yr old having inpatient noncardiac surgery at 12 academic hospitals in eight countries between 2007 and 2011. Cox proportional hazards models evaluated the adjusted relationship between candidate diagnostic criteria for BIMS and all-cause mortality within 30 days of surgery.
RESULTS: Of 16 079 participants, 2.0% (315) died and 36.1% (5810) met predefined screening criteria for bleeding. Based on independent association with 30-day mortality, BIMS was identified as bleeding leading to a postoperative haemoglobin <70 g L-1, transfusion of ≥1 unit of red blood cells, or that was judged to be the cause of death. Bleeding independently associated with mortality after noncardiac surgery occurred in 17.3% of patients (2782). Death occurred in 5.8% of patients with BIMS (161/2782), 1.3% (39/3028) who met bleeding screening criteria but not BIMS criteria, and 1.1% (115/10 269) without bleeding. BIMS was associated with mortality (adjusted hazard ratio: 1.87; 95% confidence interval: 1.42-2.47). We estimated the proportion of 30-day postoperative deaths potentially attributable to BIMS to be 20.1-31.9%.
CONCLUSIONS: Bleeding independently associated with mortality after noncardiac surgery (BIMS), defined as bleeding that leads to a postoperative haemoglobin <70 g L-1, blood transfusion, or that is judged to be the cause of death, is common and may account for a quarter of deaths after noncardiac surgery. CLINICAL TRIAL REGISTRATION: NCT00512109.
Copyright © 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  anaemia; mortality; noncardiac surgery; perioperative bleeding; postoperative outcome; transfusion

Year:  2020        PMID: 32768179     DOI: 10.1016/j.bja.2020.06.051

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  2 in total

1.  Improving 30-day postoperative mortality after surgery-expanding anesthesia's footprint in perioperative medicine.

Authors:  Martin Krause; Karsten Bartels
Journal:  Can J Anaesth       Date:  2022-07-13       Impact factor: 6.713

2.  Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery.

Authors:  Maura Marcucci; Thomas W Painter; David Conen; Kate Leslie; Vladimir V Lomivorotov; Daniel Sessler; Matthew T V Chan; Flavia K Borges; Maria J Martínez Zapata; C Y Wang; Denis Xavier; Sandra N Ofori; Giovanni Landoni; Sergey Efremov; Ydo V Kleinlugtenbelt; Wojciech Szczeklik; Denis Schmartz; Amit X Garg; Timothy G Short; Maria Wittmann; Christian S Meyhoff; Mohammed Amir; David Torres; Ameen Patel; Emmanuelle Duceppe; Kurtz Ruetzler; Joel L Parlow; Vikas Tandon; Michael K Wang; Edith Fleischmann; Carisi A Polanczyk; Raja Jayaram; Sergey V Astrakov; Mangala Rao; Tomas VanHelder; William K K Wu; Chao Chia Cheong; Sabry Ayad; Marat Abubakirov; Mikhail Kirov; Keyur Bhatt; Miriam de Nadal; Valery Likhvantsev; Pilar Paniagua Iglesisas; Hector J Aguado; Michael McGillion; Andre Lamy; Richard P Whitlock; Pavel Roshanov; David Stillo; Ingrid Copland; Jessica Vincent; Kumar Balasubramanian; Shrikant I Bangdiwala; Bruce Biccard; Andrea Kurz; Sadeesh Srinathan; Shirley Petit; John Eikelboom; Toby Richards; Peter L Gross; Pascal Alfonsi; Gordon Guyatt; Emily Belley-Cote; Jessica Spence; William McIntyre; Salim Yusuf; P J Devereaux
Journal:  Trials       Date:  2022-01-31       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.